About HER2-low and HER2-ultralow Metastatic Breast Cancer

For eligible patients with HR+/HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining) mBC who have received at least 1 line of ET in the metastatic setting1

ENHERTU expands the opportunity for HER2-directed therapy for eligible patients with mBC

HR+/​HER2-negative mBC2,a

˜Approximately 85%-90% of patients with HR+/HER2-negative mBC may have actionable levels of HER2 expression:  HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining). ˜Approximately 85%-90% of patients with HR+/HER2-negative mBC may have actionable levels of HER2 expression:  HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining).

aAs demonstrated in DESTINY-Breast06 screening data. Among the 1856 patients screened for participation in the study, 12% (225 patients) had IHC 0 with absent membrane staining, while 22% (402 patients) were classified as HER2-ultralow, defined as IHC 0 with membrane staining. IHC 1+ was observed in 45% (829 patients), and IHC 2+/ISH– in 21% (385 patients).

ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer.